CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Report for D003863: Depression NIH

(Synonyms: Depre, Depres, Depress, Depressi, Depressio, Depression, Depression,)

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (21)


Name (Synonyms) Correlation
drug387 Crisis intervention therapy Wiki 0.27
drug1665 standard treatment Wiki 0.27
drug1489 Web-based psychosocial peer-to-peer support Wiki 0.27
drug388 Cross-sectional observational study Wiki 0.27
drug1106 Questionnaire to study the psychological impact of confinement Wiki 0.27
drug1451 Use of social media during COVID-19 Wiki 0.27
drug1548 covid-19 positive pregnant women Wiki 0.27
drug1144 Registery Data Collection Wiki 0.27
drug244 COVID Convalescent Plasma Wiki 0.27
drug1397 Thymosin+standard treatment Wiki 0.27
drug1353 Taste test Wiki 0.27
drug965 PD-1 blocking antibody+standard treatment Wiki 0.27
drug940 Online survey Wiki 0.27
drug242 COVID 19 Diagnostic Test Wiki 0.27
drug239 CONVALESCENT PLASMA Wiki 0.27
drug109 Assessment of postnatal depression using the the Edinburgh questionnaire between 4 and 6 weeks after delivery Wiki 0.27
drug1382 Therapist Guided E-Therapy Wiki 0.27
drug217 Brief cognitive behavioural therapy Wiki 0.27
drug981 Pandemic control measures Wiki 0.27
drug1228 Self-Help Therapy Wiki 0.27
drug1257 Social media & news consumption Wiki 0.27

Correlated MeSH Terms (7)


Name (Synonyms) Correlation
D003866 Depressive Disorder NIH 0.60
D019052 Depression, Postpartum NIH 0.38
D019964 Mood Disorders NIH 0.27
D001008 Anxiety Disorders NIH 0.25
D040921 Stress Disorders, Traumatic NIH 0.13
D013313 Stress Disorders, Post-Traumatic NIH 0.12
D018352 Coronavirus Infections NIH 0.02

Correlated HPO Terms (1)


Name (Synonyms) Correlation
HP:0000716 Depressivity HPO 0.60

There are 14 clinical trials

Clinical Trials


1 Using a Diagnostic Taste Test as a Surrogate Biomarker to Predict Drug Effectiveness in Patients With Depression (MDD)

The study will be looking at whether a taste test device can be used as a diagnostic aid for depression. Taste tests will be carried out before and after first use of an antidepressant (prescribed by the patient's GP) and then again a month later a further taste test will be conducted. The results of these tests will be assessed to see if they correlate with the outcome of validated mood questionnaires carried out at the first and second visits.

NCT03645447 Depression Diagnostic Test: Taste test
MeSH:Depression Depressive Disorder
HPO:Depressivity

Primary Outcomes

Description: Change in taste threshold measures (sweet, salt, bitter, sour) between baseline and post-probe(s) at day 1 and 28 days after antidepressant treatment is initiated is assessed with the assistance of a taste test device.

Measure: Change in taste threshold with antidepressant treatment

Time: 4-6 weeks (per patient)

Description: Change in mood (assessed by score on the Beck Depression Inventory (BDI)) with antidepressant treatment is assessed. BDI scores may range from 0-63, where 0 demonstrates the lowest depression score and 63 the most severe depression.

Measure: Change in mood (assessed by score on the Beck Depression Inventory) with antidepressant treatment

Time: 4-6 weeks (per patient)

Secondary Outcomes

Description: Changes in scores on the Clinical Global Impression scale, as assessed by the participant's general medical practitioner is recorded. This scale ranges from 0-7, where 0 is the least severely ill and 7 the most severely ill.

Measure: Change in mood with antidepressant treatment, measured by the Clinical Global Impression Scale (CGI scale)

Time: 4-6 weeks (per patient)

Description: Change in mood with antidepressant treatment, measured by the Patient Health Questionnaire 9 (PHQ9). PHQ9 scores range from 0-27, where 0 is the score for the least depressed patients and 27 the most severely depressed patients.

Measure: Change in mood with antidepressant treatment, measured by the Patient Health Questionnaire 9 (PHQ9)

Time: 4-6 weeks (per patient)

Description: Change in mood with antidepressant treatment, measured by the Hospital Anxiety and Depression scale (HADS). HADS scores for depression range from 0-21, where 0-7 is normal, 8-10 borderline and 11+ indicates clinical depression

Measure: Change in mood with antidepressant treatment, measured by the Hospital Anxiety and Depression scale (HADS)

Time: 4-6 weeks (per patient)

Description: Change in mood with antidepressant treatment, measured by the Quick Inventory of Depressive symptomatology (QIDS). Scores for QIDS range from 0-27, where 0 indicates no symptoms of depression and 27 indicates the most severe depression.

Measure: Change in mood with antidepressant treatment, measured by the Quick Inventory of Depressive symptomatology (QIDS)

Time: 4-6 weeks (per patient)

Description: A computerised algorithm will be used to direct the taste test to assess taste sensitivity. The algorithm has been developed to direct the taste test, indicating which taste solutions should be presented to the participant in which order. Every solution presented is recorded, along with answers given. These will be examined after testing to validate the code's ability to follow the algorithm created and properly determine taste thresholds.

Measure: Validation of diagnostic algorithm, comparing the sequence of taste testing determined by the device software with the algorithm described in the software specification.

Time: 12 months (duration of trial)

Description: User views on ease of use of the device and testing process will be collected. Users will be asked to give ease of use a score from 1-5, where 1 is very easy and 5 is very difficult. Participants will also be asked whether they would use the taste test again.

Measure: User assessment of ease of use of the device and testing process.

Time: 4-6 weeks (per patient)

2 Getting it Right: Towards Responsible Social Media Use During a Pandemic

The investigators plan to conduct a cross-sectional survey to examine how social media use during COVID-19 relates to: (1) information management, (2) assessment of the situation, and (3) affect.

NCT04305574 Coronavirus Depression Anxiety Stress Behavioral: Use of social media during COVID-19
MeSH:Coronavirus Infections Depression

Primary Outcomes

Description: 3 items on fear of the situation, confidence the government can manage the situation, and assessed chance of being infected (each rated using 4-point scales: min = 1, max = 4; higher scores indicate increased confidence / likelihood / fear)

Measure: Assessment of COVID-19 situation

Time: Single measurement (upon study enrolment)

Description: 21-item validated scale assessing symptoms of depression, anxiety, and stress (DASS-21): Min score = 0, Max score = 21; higher score indicates a worse outcome

Measure: Depression, Anxiety and Stress Scale

Time: Single measurement (upon study enrolment)

Secondary Outcomes

Description: Participants' self-report of their familiarity (yes/no) and belief of specific (yes/no), and whether they shared these on social media (yes/no)

Measure: Familiarity and trust in COVID-related rumours

Time: Single measurement (upon study enrolment)

Description: Participants' assessment of how many cases there have been in COVID-19 and SARS

Measure: Availability heuristic

Time: Single measurement (upon study enrolment)

3 Mental Health of Urban Mothers (MUM) Study: A Multi-center Randomized Controlled Trial

Mental health disorders are common during pregnancy and the postnatal period, and can have serious adverse effects on the well-being of woman and child. Every tenth woman has depressive symptoms and 5% suffer major depression during pregnancy. The consequences for global mental health due to the novel coronavirus disease, COVID-19, are likely to be significant and may have long-term impact on the global burden of disease. Pregnant women may be particularly vulnerable due to partial immune suppression. Besides physical vulnerability, they could be at increased risk of mental health problems, such as anxiety, depression, and post-traumatic stress disorder (PTSD), due to social distancing leading to less support from the family and friends, and in some cases, partners not being allowed to be present during prenatal visits, labor and delivery. Furthermore, many pregnant women may feel insecure and worried about the effect of COVID-19 on their unborn child, if they get infected during pregnancy. Today, young urban women are used to utilizing internet services frequently and efficiently. Therefore, providing mental health support to pregnant women via internet may be effective in ameliorating their anxiety/depression and reduce the risk of serious mental health disorders leading to improved maternal and perinatal outcomes.

NCT04363177 Perinatal Depression COVID19 Anxiety PTSD Pregnancy Related Behavioral: Web-based psychosocial peer-to-peer support
MeSH:Depression

Primary Outcomes

Description: To investigate the impact of a web-based psychosocial intervention on EPDS in urban women living in Hong Kong and Shanghainese women. Scores of EPDS range from min = 0 to max=30. The higher the more depressed a woman is.

Measure: Edinburgh Postnatal Depression Scale (EPDS)

Time: 4-6 weeks postpartum

Secondary Outcomes

Description: Association between mental health status (EPDS, GAD7, IES-R) and COVID-19 pandemic among pregnant women. GAD 7 Generalized anxiety questionnaire IES-R Impact Event Scale to assess Post traumatic stress Disorder (PTSD) COVID-19 questionnaire

Measure: Mental health status and COVID-19

Time: 4-6 weeks postpartum

Description: Impact of web-based psychosocial intervention on mental health and pregnancy outcomes among women from different socio-economic and cultural environments. Socio-economic information gained by sociodemographic questions.

Measure: Socio-economic status

Time: 4-6 weeks postpartum

Description: Relationship between mental health status of pregnant women and rates of elective cesarean section (CS) on maternal request.

Measure: Elective CS

Time: 4-6 weeks postpartum

4 Loneliness During the Non-pharmacological Epidemiological Interventions for the COVID-19 Pandemic in Norway: Risk Factors and Associations With Psychopathology

The present study of loneliness during the COVID-19-related NPIs is part of a larger project aiming to investigate psychological reactions and symptoms associated with the current and ongoing governmental initiatives in place in Norway. The results will lead to a better understanding of the psychological effects on quarantine on the population and consequently will be relevant for the development of tailored prevention and intervention programs fit for pandemic crises. Objectives Investigate the levels of loneliness in a general population during the strict social distancing government-initiated non-pharmacological interventions (NPIs) for the COVID-19 pandemic. Investigate risk and resilience factors for loneliness and the associations between loneliness and psychopathology symptoms during the NPIs. Aims Inform the general public, policy makers, scientists, and health practitioners about the associations of the NPIs with the mental health problem of loneliness and its potential effect on psychopathology. Provide a foundation for policymakers and health-care professionals to employ interventions that protect the general public against increased psychological suffering and dysfunction during society's handling of pandemics.

NCT04365881 Loneliness, Worry, Rumination, Health Anxiety, Depression, Anxiety Other: Cross-sectional observational study
MeSH:Depression

Primary Outcomes

Description: The UCLA Loneliness Scale-8 (ULS-8) measures the frequency and intensity of aspects of the lonely experience, using a 1 (never) to 4 (always) Likert-type scale. A composite score was computed by summing the items after reverse coding when appropriate, such that higher scores indicate greater loneliness. In terms of symptoms, validated measures routinely used in clinical practice to screen symptom-levels suggestive of psychiatric diagnosis were utilized.

Measure: UCLA Loneliness Scale-8 (ULS-8)

Time: From March31st 2020 to April 7th 2020

Description: The Patient Health Questionnaire-9 (PHQ-9)16 consists of nine items covering the DSM-IV criteria for major depression scored on a four-point Likert-scale (0-3), with scores ranging from 0 to 27. High scores on the PHQ-9 reveal greater depression severity and scores above 10 are considered as the cut-off indicative of a depressive diagnosis with a sensitivity and specificity of 88%.16 The PHQ-9 has revealed good psychometric properties, as demonstrated by Kroenke et al. (2001).

Measure: Patient Health Questionnaire-9 (PHQ-9)

Time: From March31st 2020 to April 7th 2020

Description: The Generalized Anxiety Disorder-7 (GAD-7)17 consists of seven items covering the DSM-IV criteria for GAD on a four-point Likert scale (0-3) with scores ranging from 0 to 21. Higher scores reveal greater GAD symptoms, and scores above 10 are considered as the cut-off indicative of a GAD-diagnosis with a specificity of 82% and sensitivity of 89%.17 The GAD-7 has revealed construct validity and reliability (Kroenke, Spitzer, Williams, Monahan & Löwe, 2007; Löwe et al., 2008).

Measure: Generalized Anxiety Disorder-7 (GAD-7)

Time: From March31st 2020 to April 7th 2020

5 Getting it Right: Towards Responsible Social Media Use During a Pandemic (COVID-19)

In this protocol, we seek to examine the role of social media in information spread during a pandemic. As there have been few pandemics in the last decade (coinciding with the rise of social media), its use in this context remains understudied. This study hence intends to: (1) characterize the nature of social media use, (2) understand the impact of social media use, and (3) understand how to communicate accurate information.

NCT04367363 Coronavirus Depression Anxiety Stress Behavioral: Social media & news consumption
MeSH:Coronavirus Infections Depression

Primary Outcomes

Description: 21-item validated scale assessing symptoms of depression, anxiety and stress (DASS-21): Min score = 0, Max score = 21; higher score indicates a worse outcome.

Measure: Change in DASS scores across 9 days

Time: Twice: once during initial enrollment, and then 8 days after

Description: 1 item each day on fear specifically of the COVID-19 situation (measured on a 4 point scale: min = 1, max = 4; higher scores indicating greater fear about the outbreak).

Measure: Changes in fear with regards the COVID-19 situation across 1 week

Time: 1 week, starting from date after initial DASS survey completion

Description: 1 item each day on how much they thought about the outbreak that day (measured on a 5 point scale: min = 1, max = 5; higher scores indicating more thinking about the outbreak).

Measure: Changes in amount of thinking about the COVID-19 situation across 1 week

Time: 1 week, starting from date after initial DASS survey completion

6 Impact of Giving Birth During the Covid 19 Pandemia on Postnatal Women's Depression

Postnatal depression is an important problematic in French population with approximatively 10 -20% of women who suffer from postnatal depression. This pathology may have strong negative impact on both women and neonate's health. The women's satisfaction degree in front of childbirth is an important factor associated with postnatal depression since women unsatisfied of their childbirth and/or women with a complicated childbirth are more encline to suffer from postnatal depression. It is likely that the actual context of Covid 19 pandemia and the change in obstetrical cares organization may have a negative impact on women's satisfaction about their childbirth and so a negative impact on the risk of postnatal depression.

NCT04368208 Postnatal Depression Other: Assessment of postnatal depression using the the Edinburgh questionnaire between 4 and 6 weeks after delivery
MeSH:Depression, Postpartum Depression Depressive Disorder
HPO:Depressivity

Primary Outcomes

Description: proportion of women with an Edinburgh score higher than 12 between 4 and 6 weeks postpartum

Measure: Report postnatal depression between 4 of 6 weeks during the covid 19 pandemia

Time: 4-6 weeks postpartum

Secondary Outcomes

Description: Existence of an association with postnatal depression and these factors: socio demographic women's characteristics, modalities of pregnancy management, satisfaction and experience about delivery, postnatal pelvic floor disorders, self rated health for the woman and the child, modalities of delivery, prenatal anxiety

Measure: Report factors associated with postnatal depression between 4 of 6 weeks during the covid 19 pandemia

Time: 4-6 weeks postpartum

Description: Scale from 0 to 10 of satisfaction ; answers to the WOMBLSQ4 questionnaire about childbirth experience and satisfaction

Measure: Describe the experience and the satisfaction about delivery during the covid 19 pandemia

Time: within the week after delivery

7 Prevalence Of Anxiety And Depression During COVID-19

1. To understand the prevalence of symptoms of Depression and Anxiety in general population during COVID-19 in India 2. To understand correlation between COVID-19 related factors and mental health symptomology in the general population in India Hypothesis: There is likelihood of significant symptoms of depression and anxiety among general population in India during the current COVID-19 outbreak. Procedure: The participants would be selected with their informed consent. The objective of the study would be clearly written on Page 1 of the survey. The test would be administered electronically by all the participants individually only when consented to the study. The data collected will be kept strictly confidential and the identity of the participants will not be disclosed at any point of the research Measures: 1. Demographic Information Demographic variables included Gender, Age, Place of Stay, Marital Status, Highest Level ofEducation, current living arrangement (e.g. staying alone or with family) and Occupation. It further includesregular employment status and current employment status(e.g, Work from home, temporary leave, termination etc) 2. History of illness (Present or past) History of physical ailment specified (diabetes, hypertension, heart ailment or being on any steroid or any other chronic ailment) Previous history of H1N1/ Influenza like illness 3. COVID-19 Information This section includes time spent focusing on COVID related information, current stressors with respect to COVID-19 and coping mechanisms used. This further includesinformation on resources available to participants near their place of stay and information of any known diagnosed case of COVID-19. 4. Standardized Scales to be used Generalized Anxiety Disorder Scale (GAD-7); Patient Health Questionnaire (PHQ-9) Powered by

NCT04369300 COVID-19 Behavioral: Registery Data Collection
MeSH:Depression

Primary Outcomes

Description: To understand the prevalence (magnitude) of depression and anxiety of general adult population during COVID-19 using Generalized Anxiety Disorder Scale (GAD-7)

Measure: Prevalence (magnitude) of anxiety of general adult population during COVID-19

Time: 1 YEAR

Description: To understand the prevalence (magnitude) of depression and anxiety of general adult population during COVID-19 using Patient Health Questionnaire (PHQ-9).

Measure: prevalence (magnitude) of depression and anxiety of general adult population during COVID 19

Time: 1 Year

8 Level and Predictors of Trauma-symptoms Among Health Workers and Public Service Providers During the COVID-19 Outbreak

The aim of this study is to investigate the levels of trauma and mental symptoms (i.e., depression and anxiety) among health workers and public service providers during the strict social distancing government-initiated non-pharmacological interventions (NPI's) related to the COVID-19 pandemic. The study also aims to investigate predictors of trauma-symptoms.

NCT04374097 Post Traumatic Stress Disorder Anxiety Depression
MeSH:Depression Stress Disorders, Traumatic Stress Disorders, Post-Traumatic

Primary Outcomes

Description: PCL-5 is 20-item self-administered questionnaire which assesses the full domain of the DSM-5 PTSD diagnosis. The self-report rating scale is 0-4 for each symptom. Rating scale descriptors are: "Not at all," "A little bit," Moderately," "Quite a bit," and "Extremely."The PCL-5 has four subscales, corresponding to each of the symptom clusters in the DSM-5.

Measure: PTSD Checklist for DSM-5 (PCL-5)

Time: All data was collected between March 31st 2020 and April 7th 2020, a period where the NPIs (nonpharmacological interventions) against the COVID-19 pandemic were identical and constant in Norway

Secondary Outcomes

Description: The Patient Health Questionnaire 9 (PHQ-9; Kroenke, Spitzer & Williams, 2001) is used to measure symptoms of depression in accordance with the diagnostic criteria for major depressive disorder. The questionnaire consists of nine items where each is scored on a four-point Likert scale (0-3), with the range of scores from 0 to 27.

Measure: Patient Health Questionnaire 9 (PHQ-9)

Time: All data was collected between March 31st 2020 and April 7th 2020, a period where the NPIs (nonpharmacological interventions) against the COVID-19 pandemic were identical and constant in Norway

Description: The Generalized Anxiety Disorder 7 (GAD-7; Spitzer, Kroenke, Williams & Löwe, 2006) is a questionnaire consisting of seven items measuring symptoms of anxiety and worry. The items are scored on a four-point Likert scale (0-3), with the scores ranging from 0 to 21.

Measure: The Generalized Anxiety Disorder 7 (GAD-7)

Time: All data was collected between March 31st 2020 and April 7th 2020, a period where the NPIs (nonpharmacological interventions) against the COVID-19 pandemic were identical and constant in Norway]

Description: Symptoms of health anxiety was measured with two items from the validated Health Anxiety Inventory (HAI), one item measuring specific fear of being infected by coronavirus, and an item measuring fear of dying by the coronavirus. All items used a Likert scale from 0-3, and the new total score of health anxiety had a range from 0-12.

Measure: Health anxiety

Time: All data was collected between March 31st 2020 and April 7th 2020, a period where the NPIs (nonpharmacological interventions) against the COVID-19 pandemic were identical and constant in Norway

9 Descriptive Study of the PSYchological Impact of CONFinement Measures in Subjects With Mood Disorders : PsyConf

Quarantine is an unpleasant experience : separation from loved ones, loss of freedom, uncertainty about infection status, boredom .It may lead to negative mental health consequences and thus the emergence of anxiety and depressive symptoms. Poor social contacts and history of psychiatric disorders are factors increasing the negative psychological impact of confinement. Patients with psychiatric disorders are therefore particularly vulnerable during quarantine. Only one study has reported that history of psychiatric disorder was associated with a higher risk of anxiety and anger at 4 - 6 months after the end of quarantine. Since March 17th, 2020 the French government has implemented national containment measures due to the Covid-19 epidemic. This situation has led to a reorganization of care as requested on March 22nd, 2020 in the recommendations applicable to the organization of care in psychiatric services: priority to telephone contacts and teleconsultations by multiplying contacts and assessments. As part of the telephone contacts that are now part of the recommended care, patients are systematically interviewed on the impact of the confinement situation on their psychological well-being with self-questionnaires used in the daily clinical practice. Assessing the negative psychological impact in patients with a psychiatric history is essential to better deploy post-confinement management. This assessment will provide preliminary indicators for the appropriate organization of care.

NCT04374643 Depression, Unipolar COVID 19 Other: Questionnaire to study the psychological impact of confinement
MeSH:Depression Depressive Disorder Mood Disorders
HPO:Depressivity

Primary Outcomes

Description: depressive symptomatology with Patient Health Questionnaire

Measure: Depressive Symptomatology

Time: during confinement

Secondary Outcomes

Description: depressive symptomatology with Patient Health Questionnaire

Measure: Depressive Symptomatology

Time: post-confinement : 15 days, 3 months, 6 months

Other Outcomes

Description: Psychological pain : likert scale

Measure: Psychological pain

Time: confinement

Description: quality of sleep assessed with Insomnia Seveity Index

Measure: sleep

Time: confinement

Description: quality of sleep assessed with Insomnia Seveity Index

Measure: sleep

Time: post-confinement (15 days, 3 months, 6 months)

Description: anxiety intensity assessed by Generalized Anxieety Disorder

Measure: anxiety

Time: confinement

Description: anxiety intensity assessed by Generalized Anxieety Disorder

Measure: anxiety

Time: post-confinement (15 days, 3 months, 6 months)

Description: psychological pain : likert scale

Measure: psychological pain

Time: post-confinement (15 days, 3 months, 6 months)

Description: psychological pain : likert scale

Measure: physical pain

Time: confinement

Description: psychological pain : likert scale

Measure: physical pain

Time: post-confinement (15 days, 3 months, 6 months)

Description: staxi state scale

Measure: anger

Time: confinement

Description: staxi state scale

Measure: anger

Time: post-confinement (15 days, 3 months, 6 months)

Description: Assessed by the Stressful Event Impact Scale - Horowitz

Measure: Stressful Event Impact

Time: confinement

Description: Assessed by the Stressful Event Impact Scale - Horowitz

Measure: Stressful Event Impact

Time: post-confinement (15 days, 3 months, 6 months)

Description: declarative psychotropic drugs consumption

Measure: Use of psychotropic drugs

Time: confinement

Description: declarative psychotropic drugs consumption

Measure: Use of psychotropic drugs

Time: post-confinement (15 days, 3 months, 6 months)

Description: declarative consumption

Measure: Tobacco consumption

Time: confinement

Description: declarative consumption

Measure: Tobacco consumption

Time: post-confinement (15 days, 3 months, 6 months)

Description: declarative consumption

Measure: alcohol consumption

Time: post-confinement (15 days, 3 months, 6 months)

Description: declarative consumption

Measure: alcohol consumption

Time: confinement

Description: declarative consumption

Measure: Illicit substances consumption

Time: confinement

Description: declarative consumption

Measure: Illicit substances consumption

Time: post-confinement (15 days, 3 months, 6 months)

Description: LOT-R questionnaire

Measure: orientation of life

Time: confinement

Description: LOT-R questionnaire

Measure: orientation of life

Time: post-confinement (15 days, 3 months, 6 months)

10 Risk Factors for Anxiety and Depression Among Pregnant Women During the COVID-19 Pandemic - a Web-based Cross-sectional Survey

The article presents a protocol of a cross-sectional study of mental health of pregnant women in relation to the COVID 19 pandemic. The primary aim is to compare differences in anxiety and depression scores of pregnant women between countries affected by the COVID-19 pandemic. The secondary aim is to assess demographic, economic, and social aspects affecting maternal anxiety and depression scores among pregnant women worldwide in the time of the COVID-19 pandemic. Finally, investigators will be able to compare differences in perception of the different aspects of the COVID-19 pandemic (social distancing, restrictions related to delivery) between countries and according to the epidemic status (number of infected patients, number of reported deaths). The comparisons will also be done according to COVID-19 status of the participants.

NCT04377412 Anxiety Depression Pregnancy Related Other: Pandemic control measures
MeSH:Depression Depressive Disorder Anxiety Disorders
HPO:Depressivity

Primary Outcomes

Description: Anxiety measured by General Anxiety Disorder-7 (GAD-7) scale. Scoring:5-9 mild; 10-14 moderate; >15 severe. Minimum 0, maximum 21 points

Measure: Anxiety

Time: 4 months

Description: Depression measured by Patient Health Questionnaire-9 (PHQ-9) scale. Scoring: 5-9 mild;10-14 moderate; 15-19 moderately severe; >20 severe. Minimum 0 maximum 27 points

Measure: Depression

Time: 4 months

11 Efficacy of Therapist Guided e-Therapy Versus Self-Help Therapy on Psychological Distress Among Individuals in Oman During COVID-19 Pandemic: An Open-Label 12 - Weeks Randomized Controlled Trail

Background: COVID-19 (Corona Virus Disease 2019) is a virulent infectious disease with an incubation period ranging between 2-14 days. This highly contagious disease is caused by Sars-Cov-2 (Severe Acute Respiratory Syndrome Coronavirus 2). The number of people infected by COVID-19 has increased exponentially since January as a result of traveling and contact with COVID-19 infected individual. Initially, the seriousness of COVID-19 was not gauged properly until World Health Organization classified it as Pandemic type infectious disease and rapidly made plans actions to fight against it on 20 January, 2020. The uncertainty and low predictability of COVID-19 not only threaten people's physical health, but also affect people's mental health, especially in terms of emotions and cognition. As consequence of public emergency, with its economic health and social impacts, psychological repercussions among people are inevitable at the short and long term. Importance and justify the study: This study will assess the effectiveness of e therapy in treating anxiety and depression during a pandemic. This would be a novel way of providing therapy during crises Hypothesis: We hypothesize that compared to self-help email delivered therapy, the therapist guided e-Therapy is more efficacious in reducing the level of psychosocial stress among distressed individuals in Oman during COVID19. Objective: The aim of this study is to assess the efficacy of six weeks therapist guided e-Therapy versus Self-help e-mail delivered therapy on Psychological distress among random sample of individuals live in Oman during COVID 19 pandemic. This study will recruit 60 participants from a list respondents to public survey who reported high levels of depression and anxiety, and randomize them to either therapist guided e-psychotherapy(intervention) or (control) self-help arms. Participants in the intervention arm will receive six sessions of therapist guided e therapy as described in the study schedule. Participants in the control arm will receive self-help psychotherapy contents similar to the intervention arm as detailed in the study schedule. Throughout the study, outcome and safety assessments will be conducted.

NCT04378257 Depressive Symptoms Generalized Anxiety Behavioral: Therapist Guided E-Therapy Behavioral: Self-Help Therapy
MeSH:Depression

Primary Outcomes

Description: Depressive symptoms will be measured with the Patient Health Questionnaire-9 (PHQ-9) instrument. The PHQ-9 is a nine item survey to assess depressive symptoms over the previous 2 weeks. The patient may answer "not at all" (scored as a 0) , "several days" (scored as a 1), "more than half the days" (scored as a 2), or "nearly every day" (scored as a 3) for each item. The range in total scores is from 0 (no depressive symptoms or best outcome) to 27 (severe depressive symptoms or worst outcome). The primary out come measure is to calculate the change in the mean scores of PHQ-9 from baseline to the end of the study between the intervention and the control.

Measure: Change in Depressive symptoms measured by Patient Health Questionnaire-9

Time: 6-12 weeks

Description: The Generalized Anxiety Disorder 7-item scale is a 7- item self-report measure of generalized anxiety. Participants rate the frequency with which they experience anxiety-related symptoms on a scale of 0 (Not at all) to 3 (Nearly every day). Total scores range from 0-21 with higher scores indicating greater anxiety symptoms. The second primary out come measure is to calculate the change in the mean scores of GAD-7 from baseline to the end of the study between the intervention and the control.

Measure: Change in Anxiety symptoms measured by Generalized Anxiety Disorder-7

Time: 6-12 WEEKS

Secondary Outcomes

Description: Proportion of subjects with Significant Depression (Defined as PHQ-9 total score ≥ 10 ) in each arm

Measure: Proportion of subjects with Significant Depression

Time: 6-12 weeks

Description: Proportion of subjects with Significant Anxiety (Defined as GAD-7 total score ≥ 10 ) in each arm

Measure: Proportion of subjects with Significant Anxiety

Time: 6-12 weeks

12 ''(COVID-19) and Anxiety and Depressive Symptoms in Pregnant Women"

In our study; Anxiety and depression levels, socio-demographic characteristics of the pregnant women who were admitted to our hospital between 25.04.2020-25.07.2020 and treated with the diagnosis of covid 19, and the change in anxiety and depression levelsWİTH Beck Depression and Anxiety Score after the disease regressed are planned. (Beck depression scale contains 10 questions and a total of 1 to 100 points is obtained. High score indicates that depression and anxiety are high.) 0-16 points = mild depressive symptoms 17-29 points = moderate depressive symptoms 30-63 points = severe depressive symptoms

NCT04384887 COVID Anxiety Depression, Postpartum Behavioral: covid-19 positive pregnant women
MeSH:Depression, Postpartum Depression Anxiety Disorders

Primary Outcomes

Description: Evaluation of depression and anxiety score changes of covid-19 positive pregnants Pregnant women are questioned how this period was affected, as the pandemic period loaded with extra stress and caused depression and anxiety.

Measure: Evaluation of depression and anxiety score changes of covid-19 positive pregnants

Time: 4 months

13 Impact of Covid-19 Pandemic on Depression and Quality of Life: Cross Sectional Study on Turkish Society and Suggestions on Potential Solution

It is aimed to investigate the depression and quality of life of Turkish society caused by Covid-19 pandemic and reveal the relationship between them

NCT04394078 Depression Quality of Life Covid 19 Social Isolation Other: Online survey
MeSH:Depression Depressive Disorder
HPO:Depressivity

Primary Outcomes

Description: Participants are asked to give information about: age, gender, educational status, height, weight, occupation, working status, city inhabited, whether they live alone or with someone, whether they have a chronic disease, have a pet, do physical activity, eat healthy and sufficient, have qualified sleep, whether they are supported economically.

Measure: Sociodemographic information form

Time: two months after Covid 19 recognised as pandemic

Description: Zung depression scale, developed by Zung (Zung, 1965), is patient rating depression scale, was used to asses four domains related to depression; somatic, mood disorders, psychomotor and psychological disorders. Each question is rated on a 4-point Likert scale (0- never, 1- sometimes, 2- frequently, 3- always). Scale contains 10 straight 10 reverse questions. The total score is calculated from the raw score obtained (total score = (raw score / 80) * 100). Accordingly, scores less than 50 are normal or no psychopathology; between 50 and 59 points indicates mild level, between 60 and 69 points indicate moderate level and 70 and above points indicate severe level depression (Thurber et al., 2002). The validity reliability of the scale was studied on Turkish society (Gencdogan & Nihal, 2011)

Measure: Zung Depression Scale

Time: two months after Covid 19 recognised as pandemic

Description: World Health Organization Quality of Life Bref is the short version of the WHOQOL-100 to assess the health-related quality of life (Harper et al., 1998), which has efficient psychometric properties, valid and reliable for Turkish society (Eser et al., 1999). It is essential for epidemiological survey and international report has built for psychometric properties for 26 country where Turkey within (Skevington et al., 2004). It has 4 domains; physical health, psychology, social relations and environment. Each question is answered on a 5-point Likert scale. The raw score is converted into a percentage system. The quality of life is interpreted as good as it gets closer to 100% (Akvardar et al., 2006).

Measure: World Health Organization Quality of Life - Bref

Time: two months after Covid 19 recognised as pandemic

14 Effects of Cognitive Behavariol Brief Therapy on Perceived Stress Level and Anxiety, Depression and Post Trauamatic Stress Symptoms in Medical Residents and Medical Staff During CoVID 19 Pandemics

The purpose of the study is to demonstrate the effect of brief behavarioul cognitive therapy through telepsychiatry.

NCT04394455 Anxiety Depressive Symptoms Post Traumatic Stress Symptoms Behavioral: Brief cognitive behavioural therapy Behavioral: Crisis intervention therapy
MeSH:Depression Anxiety Disorders

Primary Outcomes

Description: Patient Health Questionnaire 9

Measure: Change in Depressive symptoms

Time: 3 months after psychotherapeutic intervention has started

Description: Hamilton Anxiety Rating Scale

Measure: Change in Anxiety symptoms

Time: 3 months after psychotherapeutic intervention has started

Description: Post traumatic Stress Scale for DSM 5

Measure: Change in Post traumatic Stress symptoms

Time: 3 months after psychotherapeutic intervention has started

Description: Perceived stress scale

Measure: Change in Perceived stress level

Time: 3 months after psychotherapeutic intervention has started


HPO Nodes